Page last updated: 2024-11-10

2-nonenal, (trans)-isomer

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

2-nonenal: RN given refers to cpd without isomeric designation [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

non-2-enal : An enal consisting of non-2-ene having an oxo group at the 1-position. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

(E)-non-2-enal : A monounsaturated fatty aldehyde that is (2E)-non-2-ene which is carrying an oxo group at position 1. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID5283335
CHEMBL ID450072
CHEBI ID142592
CHEBI ID61726
SCHEMBL ID102464
MeSH IDM0312101

Synonyms (72)

Synonym
LS-13683
einecs 219-562-5
fema no. 3213
alpha-nonenyl aldehyde
3-hexyl-2-propenal
beta-hexylacrolein
ccris 3326
nsc 20746
ai3-36268
heptylideneacetaldehyde
trans-2-nonenal (natural)
3-hexylacrolein
2-nonenal, (2e)-
2-trans-nonenal
trans-2-nonen-1-al
trans-2-nonenal
ccris 9203
(e)-non-2-enal
brn 1722170
einecs 242-609-6
2463-53-8
2-nonen-1-al
non-2-enal
2-nonenal
(e)-2-nonenal
2-nonenal, (e)-
trans-2-nonenal, >=95%, fg
LMFA06000041
trans-2-nonenal, 97%
(e)-2-nonen-1-al
t-2-nonenal
trans-2-nonealdehyde
heptylidene acetaldehyde
CHEMBL450072
18829-56-6
N0430
N0483
(2e)-non-2-enal
CHEBI:142592
(2e)-2-nonenal
trans-non-2-enal
(2e)-nonenal
NCGC00248181-01
CHEBI:61726 ,
3-hexyl-acrolein
93c6bzw2tv ,
unii-93c6bzw2tv
8veo649985 ,
unii-8veo649985
4-01-00-03502 (beilstein handbook reference)
dtxcid8027086
cas-18829-56-6
NCGC00254719-01
tox21_300815
dtxsid0047086 ,
AKOS015902295
SCHEMBL102464
2-nonenal, trans-
(e)-2-nonenal [fcc]
2-nonenal [mi]
2-nonenal [fhfi]
.beta.-hexylacrolein
.alpha.-nonenyl aldehyde
mfcd00007012
trans-2-nonenal, analytical standard
J-012128
Q4596912
AS-17376
?2-nonenal
EN300-396736
trans-2-nonenal-d2
EN300-1664833

Research Excerpts

Toxicity

ExcerptReferenceRelevance
"This study investigates the toxic effect of E(2)nonenal (trans-2-nonenal, T2N) and its conjugate with horse muscle myoglobin (Mb) tested on murine cell line L929 and human cell line A549, as well as the genotoxic effect of these compounds assayed by measuring of micronuclei in human cells K562."( The cytotoxic and genotoxic effects of conjugated trans-2-nonenal (T2N), an off-flavor compound in beer and heat processed food arising from lipid oxidation.
Danielsson, B; Dey, ES; Gamian, A; Konopacka, M; Paściak, M; Rogoliński, J; Staniszewska, M, 2005
)
0.33
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
plant metaboliteAny eukaryotic metabolite produced during a metabolic reaction in plants, the kingdom that include flowering plants, conifers and other gymnosperms.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
monounsaturated fatty aldehydeAny fatty aldehyde with one double or triple bond located at any position in the aliphatic chain.
enalAn alpha,beta-unsaturated aldehyde of general formula R(1)R(2)C=CR(3)-CH=O in which the aldehydic C=O function is conjugated to a C=C double bond at the alpha,beta position.
medium-chain fatty aldehydeAny fatty aldehyde with a chain length between C6 and C12.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (2)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
AR proteinHomo sapiens (human)Potency0.06120.000221.22318,912.5098AID1259243; AID1259381
estrogen nuclear receptor alphaHomo sapiens (human)Potency54.94100.000229.305416,493.5996AID743069
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (10)

Assay IDTitleYearJournalArticle
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1081320Nematicidal activity against Bursaphelenchus xylophilus assessed as mortality at 0.0625 mg/ml measured after 48 hr under microscope2010Journal of agricultural and food chemistry, Feb-10, Volume: 58, Issue:3
Structure-activity relationship of aliphatic compounds for nematicidal activity against pine wood nematode (Bursaphelenchus xylophilus).
AID1081323Nematicidal activity against Bursaphelenchus xylophilus at 0.5 mg/ml measured after 48 hr under microscope2010Journal of agricultural and food chemistry, Feb-10, Volume: 58, Issue:3
Structure-activity relationship of aliphatic compounds for nematicidal activity against pine wood nematode (Bursaphelenchus xylophilus).
AID549523Antimalarial activity against chloroquine-resistant Plasmodium falciparum W2 infected in human A-positive red blood cells after 72 hrs by lactate dehydrogenase assay2011Bioorganic & medicinal chemistry, Jan-01, Volume: 19, Issue:1
Antimalarials based on the dioxane scaffold of plakortin. A concise synthesis and SAR studies.
AID1081322Nematicidal activity against Bursaphelenchus xylophilus assessed as mortality at 0.25 mg/ml measured after 48 hr under microscope2010Journal of agricultural and food chemistry, Feb-10, Volume: 58, Issue:3
Structure-activity relationship of aliphatic compounds for nematicidal activity against pine wood nematode (Bursaphelenchus xylophilus).
AID468443Inhibition of human FAAH at 1 uM2009Bioorganic & medicinal chemistry letters, Dec-01, Volume: 19, Issue:23
Mining biologically-active molecules for inhibitors of fatty acid amide hydrolase (FAAH): identification of phenmedipham and amperozide as FAAH inhibitors.
AID549522Antimalarial activity against chloroquine-sensitive Plasmodium falciparum D10 infected in human A-positive red blood cells after 72 hrs by lactate dehydrogenase assay2011Bioorganic & medicinal chemistry, Jan-01, Volume: 19, Issue:1
Antimalarials based on the dioxane scaffold of plakortin. A concise synthesis and SAR studies.
AID1081321Nematicidal activity against Bursaphelenchus xylophilus assessed as mortality at 0.125 mg/ml measured after 48 hr under microscope2010Journal of agricultural and food chemistry, Feb-10, Volume: 58, Issue:3
Structure-activity relationship of aliphatic compounds for nematicidal activity against pine wood nematode (Bursaphelenchus xylophilus).
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (85)

TimeframeStudies, This Drug (%)All Drugs %
pre-19903 (3.53)18.7374
1990's13 (15.29)18.2507
2000's33 (38.82)29.6817
2010's27 (31.76)24.3611
2020's9 (10.59)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other86 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]